Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Rhythm Pharmaceuticals (RYTM) over the last 10 years, with Q3 2025 value amounting to $66.3 million.

  • Rhythm Pharmaceuticals' Shares Outstanding (Weighted Average) rose 823.45% to $66.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.3 million, marking a year-over-year increase of 823.45%. This contributed to the annual value of $61.0 million for FY2024, which is 576.02% up from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Shares Outstanding (Weighted Average) stood at $66.3 million for Q3 2025, which was up 823.45% from $63.7 million recorded in Q2 2025.
  • Rhythm Pharmaceuticals' Shares Outstanding (Weighted Average)'s 5-year high stood at $66.3 million during Q3 2025, with a 5-year trough of $47.6 million in Q1 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $56.9 million (2023), whereas its average is $56.2 million.
  • As far as peak fluctuations go, Rhythm Pharmaceuticals' Shares Outstanding (Weighted Average) skyrocketed by 1385.66% in 2021, and later skyrocketed by 37.55% in 2022.
  • Over the past 5 years, Rhythm Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarter) stood at $49.6 million in 2021, then rose by 5.08% to $52.1 million in 2022, then grew by 10.65% to $57.7 million in 2023, then increased by 5.76% to $61.0 million in 2024, then rose by 8.63% to $66.3 million in 2025.
  • Its last three reported values are $66.3 million in Q3 2025, $63.7 million for Q2 2025, and $63.1 million during Q1 2025.